Prof Martin Dreyling discusses the safety profile of the BTK inhibitor acalabrutinib in patients with mantle cell lymphoma.

In an interview, Prof Martin Dreyling discussed the approval of first-line acalabrutinib for the treatment of adult patients ...

AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a ...

ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...

AstraZeneca has successfully completed the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell ...

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton ...

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

AstraZeneca now has 16 blockbuster medicines in its portfolio with sales exceeding $1 billion, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza (partnered with Merck [MRK]), Calquence and ...

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers ...